Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound.

MLA

McEvoy, Aubriana M., et al. “Cost-Effectiveness Analyses Demonstrate That Observation Is Superior to Sentinel Lymph Node Biopsy for Postmenopausal Women with HR + Breast Cancer and Negative Axillary Ultrasound.” Breast Cancer Research and Treatment, vol. 183, no. 2, Sept. 2020, pp. 251–62. EBSCOhost, https://doi.org/10.1007/s10549-020-05768-2.

APA

McEvoy, A. M., Poplack, S., Nickel, K., Olsen, M. A., Ademuyiwa, F., Zoberi, I., Odom, E., Yu, J., Chang, S.-H., & Gillanders, W. E. (2020). Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound. Breast Cancer Research and Treatment, 183(2), 251–262. https://doi.org/10.1007/s10549-020-05768-2

Chicago

McEvoy, Aubriana M, Steven Poplack, Katelin Nickel, Margaret A Olsen, Foluso Ademuyiwa, Imran Zoberi, Elizabeth Odom, Jennifer Yu, Su-Hsin Chang, and William E Gillanders. 2020. “Cost-Effectiveness Analyses Demonstrate That Observation Is Superior to Sentinel Lymph Node Biopsy for Postmenopausal Women with HR + Breast Cancer and Negative Axillary Ultrasound.” Breast Cancer Research and Treatment 183 (2): 251–62. doi:10.1007/s10549-020-05768-2.